Yoshiki Higashijima
Overview
Explore the profile of Yoshiki Higashijima including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
25
Citations
432
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhao P, Higashijima Y, Sonoda H, Morinaga R, Uema K, Oguchi A, et al.
J Pharmacol Sci
. 2024 Aug;
156(2):115-124.
PMID: 39179330
Although several studies have shown that glucocorticoids exert diuretic effects in animals and humans, the underlying mechanism responsible for the acute diuretic effect remains obscure. Here we examined the mechanism...
2.
Sonoda H, Taniguchi Y, Fujimoto N, Higashijima Y, Matsuzaki T, Hirai T, et al.
J Vet Med Sci
. 2024 Aug;
86(10):1063-1067.
PMID: 39143016
The role of aquaporin proteins (AQPs) in tumor biology has attracted attention over the past 20 years. However, the expression profiles of AQPs in canine sebaceous gland tumors remain obscure....
3.
Narita T, Higashijima Y, Kilic S, Liebner T, Walter J, Choudhary C
Nat Genet
. 2023 Apr;
55(4):679-692.
PMID: 37024579
Chromatin features are widely used for genome-scale mapping of enhancers. However, discriminating active enhancers from other cis-regulatory elements, predicting enhancer strength and identifying their target genes is challenging. Here we...
4.
Sasaki Y, Higashijima Y, Suehiro J, Sugasawa T, Oguri-Nakamura E, Fukuhara S, et al.
Biochem Biophys Res Commun
. 2022 Mar;
605:16-23.
PMID: 35306360
Vascular endothelial growth factor (VEGF) signaling plays a central role in vascular development and maintenance of vascular homeostasis. In endothelial cells (ECs), VEGF activates the gene expression of angiogenic transcription...
5.
Kanki Y, Muramatsu M, Miyamura Y, Kikuchi K, Higashijima Y, Nakaki R, et al.
Cell Rep
. 2022 Feb;
38(6):110332.
PMID: 35139389
Endothelial cells (ECs) are phenotypically heterogeneous, mainly due to their dynamic response to the tissue microenvironment. Vascular endothelial cell growth factor (VEGF), the best-known angiogenic factor, activates calcium-nuclear factor of...
6.
Shimizu T, Taguchi A, Higashijima Y, Kanki Y, Nakaki R, Urade Y, et al.
Sci Rep
. 2021 Sep;
11(1):18687.
PMID: 34548576
Peripartum cardiomyopathy (PPCM) is a life-threatening heart failure occurring in the peripartum period. Although mal-angiogenesis, induced by the 16-kDa N-terminal prolactin fragment (16 K PRL), is involved in the pathogenesis,...
7.
Higashijima Y, Kanki Y
FEBS J
. 2021 Jun;
289(19):5762-5775.
PMID: 34173323
Acute and chronic inflammation is a basic pathological event that contributes to atherosclerosis, cancer, infectious diseases, and immune disorders. Inflammation is an adaptive process to both external and internal stimuli...
8.
Narita T, Ito S, Higashijima Y, Chu W, Neumann K, Walter J, et al.
Mol Cell
. 2021 Mar;
81(10):2166-2182.e6.
PMID: 33765415
The metazoan-specific acetyltransferase p300/CBP is involved in activating signal-induced, enhancer-mediated transcription of cell-type-specific genes. However, the global kinetics and mechanisms of p300/CBP activity-dependent transcription activation remain poorly understood. We performed...
9.
PERK inhibition attenuates vascular remodeling in pulmonary arterial hypertension caused by mutation
Shimizu T, Higashijima Y, Kanki Y, Nakaki R, Kawamura T, Urade Y, et al.
Sci Signal
. 2021 Jan;
14(667).
PMID: 33500333
Pulmonary arterial hypertension (PAH) is a fatal disease characterized by excessive pulmonary vascular remodeling. However, despite advances in therapeutic strategies, patients with PAH bearing mutations in the bone morphogenetic protein...
10.
Higashijima Y, Nangaku M
Kidney Int
. 2020 Dec;
98(6):1367-1369.
PMID: 33276860
No abstract available.